Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Jichi Medical University currently has 3 pending office actions distributed across the Biotechnology & Pharmaceuticals technology area. The portfolio shows a prosecution landscape with 3 distinct examiners and 3 distinct art units involved. This equal count between pending actions, examiners, and art units suggests that the active matters are being handled by different individuals, potentially indicating a variety of distinct research projects.
The busiest examiner, SHEN, WU CHENG WINSTON, is responsible for 1 busiest examiner pending office action. Because the total volume is 3 pending office actions, the busiest examiner pending count is lower than the total, meaning no examiner handles the majority of the work. This distribution across the 3 distinct examiners requires the university to manage different examiner styles and art unit expectations simultaneously.
The involvement of the 3 distinct art units further highlights the breadth of the university's current Biotechnology & Pharmaceuticals filings. With the pending office actions spread across these different units, the prosecution strategy must be adaptable to different technical standards. The data indicates that SHEN, WU CHENG WINSTON and the other examiners play a role in the current active portfolio status for Jichi Medical University.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHEN, WU CHENG WINSTON | 1 | 23.7% | +25.5% |
| XU, QING | 1 | 50.9% | +55.2% |
| MARLEN, TAMMIE K | 1 | 75.2% | +21.0% |
| GRABER, JAMES J | 1 | 46.7% | +57.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17176390 | PHYSIOLOGICAL INFORMATION PROCESSING APPARATUS, PHYSIOLOGICAL INFORMATION PROCESSING METHDO AND STORAGE MEDIUM | MARLEN, TAMMIE K | 12d |
| 17914323 | TEMPORARY TREATMENT MEDIUM, TREATMENT KIT, EMBRYOGENESIS ARREST INHIBITOR, EMBRYOGENESIS ARREST INHIBITORY METHOD, DEVELOPMENTAL ENGINEERING PRODUCT PREPARATION METHOD, TRANSPLANTATION METHOD, THERAPEUTIC METHOD, AND DEVELOPMENTAL ENGINEERING PRODUCT | SHEN, WU CHENG WINSTON | — |
| 17042819 | GENOME EDITING METHOD, COMPOSITION, CELL, CELL PREPARATION, AND METHOD FOR PRODUCING CELL PREPARATION | GRABER, JAMES J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17176390 | PHYSIOLOGICAL INFORMATION PROCESSING APPARATUS, PHYSIOLOGICAL INFORMATION PROCESSING METHDO AND STORAGE MEDIUM | MARLEN, TAMMIE K | 12d |
| 17782531 | PREPARATION OF ADIPOSE TISSUE-DERIVED CELL POPULATION | XU, QING | 21d |
| 17914323 | TEMPORARY TREATMENT MEDIUM, TREATMENT KIT, EMBRYOGENESIS ARREST INHIBITOR, EMBRYOGENESIS ARREST INHIBITORY METHOD, DEVELOPMENTAL ENGINEERING PRODUCT PREPARATION METHOD, TRANSPLANTATION METHOD, THERAPEUTIC METHOD, AND DEVELOPMENTAL ENGINEERING PRODUCT | SHEN, WU CHENG WINSTON | — |
| 17042819 | GENOME EDITING METHOD, COMPOSITION, CELL, CELL PREPARATION, AND METHOD FOR PRODUCING CELL PREPARATION | GRABER, JAMES J | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1656 | 1 |
| 3796 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914323 | TEMPORARY TREATMENT MEDIUM, TREATMENT KIT, EMBRYOGENESIS ARREST INHIBITOR, EMBRYOGENESIS ARREST INHIBITORY METHOD, DEVELOPMENTAL ENGINEERING PRODUCT PREPARATION METHOD, TRANSPLANTATION METHOD, THERAPEUTIC METHOD, AND DEVELOPMENTAL ENGINEERING PRODUCT | SHEN, WU CHENG WINSTON | 1682 | §102§103§112 | Non-Final OA | — | Pending | Sep 24, 2022 |
| 17782531 | PREPARATION OF ADIPOSE TISSUE-DERIVED CELL POPULATION | XU, QING | 1656 | §103 | Non-Final OA | 21d | Pending | Jun 03, 2022 |
| 17176390 | PHYSIOLOGICAL INFORMATION PROCESSING APPARATUS, PHYSIOLOGICAL INFORMATION PROCESSING METHDO AND STORAGE MEDIUM | MARLEN, TAMMIE K | 3796 | §101§102§103§112 | Non-Final OA | 12d | Pending | Feb 16, 2021 |
| 17042819 | GENOME EDITING METHOD, COMPOSITION, CELL, CELL PREPARATION, AND METHOD FOR PRODUCING CELL PREPARATION | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | Sep 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial